Eli Lilly, Boehringer Ingelheim get approval to expand Jardiance, Synjardy labels to kids with type 2 diabetes
Eli Lilly and Boehringer Ingelheim won FDA approval to expand empagliflozin’s label to include adolescents with type 2 diabetes.
The SGLT2 inhibitor, better known as …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
